Medytox (Exclusive Right To Develop Neurotoxin Products) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Medytox (Exclusive Right To Develop Neurotoxin Products) General Information

Description

Portfolio of rights to commercialize neurotoxin products. The portfolio provides exclusive rights, outside of Korea, and co-exclusive rights in Japan, to develop and commercialize certain neurotoxin product candidates including a potential liquid-injectable product.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 78, Gagni 1-Gil, Ochang-Eup
  • Cheongwon-Gu, Chungcheongbuk-Do
  • Cheongju, 363-883
  • South Korea
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Acquirer
Allergan
Corporate Office
  • 78, Gagni 1-Gil, Ochang-Eup
  • Cheongwon-Gu, Chungcheongbuk-Do
  • Cheongju, 363-883
  • South Korea

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medytox (Exclusive Right To Develop Neurotoxin Products) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Medytox (Exclusive Right To Develop Neurotoxin Products)‘s full profile, request access.

Request a free trial

Medytox (Exclusive Right To Develop Neurotoxin Products) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Medytox (Exclusive Right To Develop Neurotoxin Products)‘s full profile, request access.

Request a free trial

Medytox (Exclusive Right To Develop Neurotoxin Products) FAQs

  • Where is Medytox (Exclusive Right To Develop Neurotoxin Products) headquartered?

    Medytox (Exclusive Right To Develop Neurotoxin Products) is headquartered in Cheongju, South Korea.

  • What industry is Medytox (Exclusive Right To Develop Neurotoxin Products) in?

    Medytox (Exclusive Right To Develop Neurotoxin Products)’s primary industry is Buildings and Property.

  • Is Medytox (Exclusive Right To Develop Neurotoxin Products) a private or public company?

    Medytox (Exclusive Right To Develop Neurotoxin Products) is a Private company.

  • What is the current valuation of Medytox (Exclusive Right To Develop Neurotoxin Products)?

    The current valuation of Medytox (Exclusive Right To Develop Neurotoxin Products) is 00000.

  • What is Medytox (Exclusive Right To Develop Neurotoxin Products)’s current revenue?

    The current revenue for Medytox (Exclusive Right To Develop Neurotoxin Products) is 000000.

  • Who are Medytox (Exclusive Right To Develop Neurotoxin Products)’s investors?

    Medytox has invested in Medytox (Exclusive Right To Develop Neurotoxin Products).

  • When was Medytox (Exclusive Right To Develop Neurotoxin Products) acquired?

    Medytox (Exclusive Right To Develop Neurotoxin Products) was acquired on 07-Jan-2014.

  • Who acquired Medytox (Exclusive Right To Develop Neurotoxin Products)?

    Medytox (Exclusive Right To Develop Neurotoxin Products) was acquired by Allergan.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »